What NanoACi 100 is and what it is formally designed to do

NanoACi 100 is the officially designated evidence programme for NanoACi™ — Professor Paul Lee's surgeon-led, non-arthroscopic, needle-delivered, one-stage autologous chondrogenic injection technique, developed at London Cartilage Clinic, 66 Harley Street, London. Its formally approved purpose is a single, precise one: to 'create a prospective body of outcomes for the combined technique.'

That scope matters. NanoACi 100 is not a registry, a branded label, or a marketing initiative. It is the structural mechanism by which sequentially enrolled real-world cases are converted into a verifiable, organised dataset for the full three-part protocol — autologous auricular cartilage micrografts, a cell-free type I collagen scaffold, and autologous platelet-rich fibrin — as Professor Lee performs it in combination. The programme is distinct from the technique itself: NanoACi is how the procedure is performed; NanoACi 100 is how its outcomes are measured, recorded, and built into a body of evidence over time.

Professor Lee's position is direct: 'Belief starts the work. Measurement earns the trust.' NanoACi 100 is the measurement.

The component evidence that already underpins NanoACi

Behind each of NanoACi's three biological roles sits a body of published evidence gathered independently before the combined protocol was assembled.

The seed — autologous auricular cartilage micrografts — draws on neural-crest biology and clinical micrografting studies recording sustained reductions in pain and improvements in function across multi-year follow-up. The scaffold, a cell-free native type I collagen matrix, has trial evidence against microfracture and more than a decade of documented use across multiple joints. The signal, autologous platelet-rich fibrin, carries published credentials as a source of sustained growth-factor release at the repair site.

A fourth evidence layer sits between scaffold and seed: published data on pairing a collagen scaffold with regenerative cells in joint repair — including in end-stage knees. Professor Lee describes this pairing as 'the load-bearing wall of NanoACi's logic,' underscoring that the rationale for combining scaffold and micrografts is not novel conjecture but a clinically studied relationship.

Together, these strands are what the approved evidence statement means when it confirms that component evidence is available. They form the scientific platform on which NanoACi 100 is built — and from which prospective combined-protocol outcomes will now be measured.

The specific gap NanoACi 100 is built to close

Each individual component's credentials — established before the combined protocol was assembled — confirm that the elements are credible in isolation. What they cannot confirm is how the three work together as a system, in the clinical context where Professor Paul Lee delivers them. The exact protocol — this scaffold, these cells, this fibrin, in combination — has not yet been through long randomised trials.

NanoACi 100 is the structured answer to that question. Its prospective design means that sequentially enrolled cases contribute to a dataset whose analysis pathway, reporting timeline, and authorship accountability were all agreed before case one — turning clinical practice into organised, verifiable evidence for the full three-part combination.

Professor Lee's framing is direct: 'Belief starts the work. Measurement earns the trust.' Naming the gap and building a programme specifically to close it is how credible science progresses. NanoACi 100 is the natural next step for a rationally designed technique built from individually supported components — the point at which component confidence gives way to combined-protocol proof, gathered patiently and honestly, over years.

Governance agreed before case one

Each of those four pre-agreed requirements — dataset, outcomes schedule, reporting plan, and publication authorship — carries practical weight that is worth unpacking separately.

The dataset defines precisely what is recorded for each enrolled case: the clinical variables, imaging findings, and patient-reported results that together constitute the raw material of the evidence. The outcomes schedule determines when those measurements are taken — the fixed time-points at which the dataset is updated, ensuring that results are not captured selectively or only when they look favourable. The reporting plan governs how findings move from the dataset into the public record: the format, the venue, and the timeline by which the programme's results become available for independent scrutiny. Publication authorship establishes who is accountable for what is reported — a discipline that commits named individuals to the integrity of the dataset before a single case is enrolled.

The Brand Guidelines add a further standing requirement: evidence statements within the programme must be linked to sources and reviewed, with component-level evidence clearly labelled and kept distinct from combined-protocol findings. That separation — already reflected in the approved public-facing description of NanoACi's evidence status — is embedded as a structural rule of the programme itself, not left to editorial discretion.

Taken together, these requirements are what convert NanoACi 100 from a named aspiration into a genuine roadmap: governance designed to prospective standards before clinical data collection begins.

How sequential enrolment turns clinical cases into verifiable data

Prospective enrolment is the methodological backbone of the NanoACi 100 roadmap. Every case is measured forward from the point of treatment — clinical variables, imaging data, and patient-reported results are captured as they occur, not assembled later from historical records. That distinction matters because retrospective case reviews, however carefully conducted, introduce selection bias: outcomes are in practice gathered with the benefit of knowing what happened. Prospective design removes that distortion by committing to the measurement architecture before any outcome is known.

The '100' in NanoACi 100 refers to a sequential enrolment target, not a trial-arm comparison. Cases enter the dataset in the order they occur; none is added because its outcome looked favourable, and none is omitted because it did not. That sequence is what builds an unselected, verifiable record of how the combined protocol performs across a real clinical population — something component-level studies, however strong individually, cannot provide.

The approved description of the programme — 'Component evidence is available; combined-protocol outcomes are being developed through NanoACi 100' — reflects this accumulating, in-progress character precisely. Each enrolled case adds a verifiable data point to the pre-agreed analysis pathway, moving the programme incrementally from clinical practice towards published proof for the full three-part technique.

Evidence built patiently and honestly, over years

Professor Lee has been explicit about the pace this requires: the evidence must be built 'patiently and honestly, over years.' That is not a caveat — it is a design principle. NanoACi 100's value accumulates case by case, prospectively and in sequence, until the complete dataset gives the full three-part technique an evidential standing that no amount of component-level research can substitute for.

The concrete milestone is the completion of the 100-case enrolment. At that point, prospective combined-protocol outcomes — captured against the pre-agreed dataset, outcomes schedule, and reporting plan established before case one — will stand alongside the independent component evidence described earlier in this article. That is what a mature evidence roadmap produces: not a claim made in advance of the data, but a dataset built in full view, accountable to named authors and a defined publication pathway.

'A name can start a movement. Evidence is what makes it last.' For NanoACi 100, the movement is already under way. The evidence is what is being built to follow it.